Company intelligence / Profile preview

Taizhou Hanzhong Biomedical

Taizhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

HX008, a humanized anti-PD-1 monoclonal antibody, has shown strong activity in Phase Ib/II trials in advanced gastric and gastroesophageal junction cancer, and is involved in multiple Phase 3 programs. Combination with chemotherapy yielded an objective response rate of 60% and a disease control rate of 77%.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Akeso

Beyond the preview

Go deeper on Taizhou Hanzhong Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taizhou Hanzhong Biomedical.

Explore the full profile